Mankind Pharma’s modern trade and e-commerce mix rises to 15% in Q1 FY27
Mankind Pharma’s consumer healthcare business grew 4% in Q1 FY27, while modern trade and e-commerce expanded 38% and increased their revenue contribution to 15%, from 11% a year earlier. Overall revenue rose 13% and EBITDA margin expanded to 26.2%.
Mankind Pharma posted strong Q1 FY27 earnings, led by domestic chronic therapies and margin expansion. Consumer healthcare grew 4%, while modern trade and e-commerce grew 38% and contributed 15% of the segment’s revenue, with market-share gains in key OTC brands.
Why this matters
The channel mix shift follows Mankind Pharma’s recent warning that the West Asia conflict was lifting petroleum-linked input costs and could lead to condom price hikes.
Omni-channel signals are accelerating, up 181,900% QoQ.